Company: IOBT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0000950170-25-058699
Chunk: 30

Company: IO Biotech, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 30
---
 applicable vesting date, and subject to 50% acceleration of any unvested portion upon a change of control and subject to 100% acceleration upon termination of service by the company without cause or by the named executive officer for good reason within 24 months of a change of control. (3) These options vest in 1/48 monthly increments of the vesting commencement date of November 4, 2021, subject to the named executive officer’s continued service through the applicable vesting date, and subject to 50% acceleration of any unvested portion upon a change of control and subject to 100% acceleration upon termination of service by the company without cause or by the named executive officer for good reason within 24 months of a change of control. (4) Warrants expire in annual increments on the fifth anniversary of the vesting date. (5) One-fourth of these options vested on March 20, 2024, and 1/36th of the remaining options vested or are scheduled to vest each month thereafter, subject to the named executive officer’s continued service through the applicable vesting date, and subject to 50% acceleration upon a change of control and subject to 100% acceleration upon termination of service without cause within 24 months of a change of control. (6) One-fourth of these options vested on March 15, 2025 and 1/36th of the remaining options vest each month thereafter, subject to the named executive officer’s continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the Company without cause and 100% acceleration upon termination of service by the Company without cause if such termination occurs within 24 months of a change of control.

<div align='center'>23</div>

One-fourth of these options vested on July 17, 2024 and 1/36th of the remaining options vest each month thereafter, subject to the named executive officer’s continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the Company without cause and 100% acceleration upon termination of service by the Company without cause if such termination occurs within 24 months of a change of control.

One-fourth of these options vested on October 17, 2023, and 1/36th of the remaining options vested or are scheduled to vest each month thereafter, subject to the named executive officer’s continued service through the applicable vesting date, and subject to